BioCentury | Feb 22, 2019
Company News

SCM, Genexine purchase Argos

...include GMP cell therapy manufacturing facilities, personnel and two clinical programs -- rocapuldencel-t (AGS-003) and AGS-004...
...CEO BG Rhee said additional analyses showed the therapy worked in a subset of patients. AGS-004...
...Lifescience, Incheon, South Korea Genexine Inc. (KOSDAQ:095700), Seoul, South Korea Business: Cancer, Infectious, Gene/Cell therapy Chris Lieu AGS-004 rocapuldencel-t...
BioCentury | Jun 27, 2016
Company News

Adaptive Biotechnologies, Argos deal

...The companies partnered to study immune responses induced by Argos’ AGS-003 and AGS-004 immunotherapies. Adaptive will...
...immunotherapy. The product is in Phase III testing to treat metastatic renal cell carcinoma (RCC). AGS-004...
BioCentury | Apr 20, 2015
Company News

Argos, Chongqing Lummy Pharmaceutical deal

...development costs required for approval. Lummy also gained an option to develop and commercialize Argos’ AGS-004...
BioCentury | Apr 15, 2015
Company News

Lummy gains Chinese rights to Argos' AGS-003

...corporate development and strategy, told BioCentury Lummy also gained an option to develop and commercialize AGS-004...
...RNA antigens. It is in Phase II testing to treat chronic HIV-1 infection. Leland said AGS-004...
BioCentury | Jan 12, 2015
Clinical News

AGS-004: Phase IIb data

...double-blind, North American Phase IIb trial in 54 patients with chronic HIV-1 infection showed that AGS-004...
...a ³1.1 log reduction in viral load after the 12-week ART interruption period vs. placebo. AGS-004...
...suggest that AGS-004-induced antiviral memory T cell responses “may contribute to lower persistent viral reservoirs.” AGS-004...
BioCentury | Jan 9, 2015
Clinical News

Argos falls on Phase IIb miss in HIV

...Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed...
...weeks of antiretroviral therapy interruption vs. placebo in a Phase IIb trial to treat HIV. AGS-004...
BioCentury | Jun 24, 2013
Regulation

Of cures & co-morbidities

...cell therapy AGS-004 in combination with HDAC inhibitor Zolinza vorinostat from Merck & Co. Inc. AGS-004...
...HIV RNA antigens. "The HDAC inhibitor will activate the reservoir of latent HIV and then AGS-004...
...virus, potentially curing the patient," Nicolette told BioCentury. An ongoing Phase II trial is evaluating AGS-004...
BioCentury | Mar 12, 2012
Finance

Argos plowing ahead

...450 patients. Abbey noted Argos has always intended to run the trial without a partner. AGS-004...
BioCentury | Mar 7, 2012
Financial News

Argos pulls IPO

...up to $86.3 million last July. Argos is developing autologous dendritic cell immunotherapies AGS-003 and AGS-004...
...III testing next quarter of AGS-003 to treat newly diagnosed metastatic renal cell carcinoma (RCC). AGS-004...
BioCentury | Feb 17, 2012
Financial News

Argos sets IPO range

...to raise up to $86.3 million. Argos is developing autologous dendritic cell immunotherapies AGS-003 and AGS-004...
...III testing next quarter of AGS-003 to treat newly diagnosed metastatic renal cell carcinoma (RCC). AGS-004...
Items per page:
1 - 10 of 24